Melanoma-Derived Exosomes Induce PD-1 Overexpression and Tumor Progression via Mesenchymal Stem Cell Oncogenic Reprogramming

Recently, it has been described that programmed cell death protein 1 (PD-1) overexpressing melanoma cells are highly aggressive. However, until now it has not been defined which factors lead to the generation of PD-1 overexpressing subpopulations. Here, we present that melanoma-derived exosomes, con...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in immunology Vol. 10; p. 2459
Main Authors Gyukity-Sebestyén, Edina, Harmati, Mária, Dobra, Gabriella, Németh, István B, Mihály, Johanna, Zvara, Ágnes, Hunyadi-Gulyás, Éva, Katona, Róbert, Nagy, István, Horváth, Péter, Bálind, Árpád, Szkalisity, Ábel, Kovács, Mária, Pankotai, Tibor, Borsos, Barbara, Erdélyi, Miklós, Szegletes, Zsolt, Veréb, Zoltán J, Buzás, Edit I, Kemény, Lajos, Bíró, Tamás, Buzás, Krisztina
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 18.10.2019
Subjects
exosome
Immunology
melanoma/tumor progression
PD-1
reprogramming
signalization pattern
stem cell
reprogramming
stem cell
metastasis
melanoma/tumor progression
signalization pattern
PD-1
exosome
Online AccessGet full text

Cover

More Information
Summary:Recently, it has been described that programmed cell death protein 1 (PD-1) overexpressing melanoma cells are highly aggressive. However, until now it has not been defined which factors lead to the generation of PD-1 overexpressing subpopulations. Here, we present that melanoma-derived exosomes, conveying oncogenic molecular reprogramming, induce the formation of a melanoma-like, PD-1 overexpressing cell population (mMSC ) from naïve mesenchymal stem cells (MSCs). Exosomes and mMSC cells induce tumor progression and expression of oncogenic factors . Finally, we revealed a characteristic, tumorigenic signaling network combining the upregulated molecules (e.g., PD-1, MET, RAF1, BCL2, MTOR) and their upstream exosomal regulating proteins and miRNAs. Our study highlights the complexity of exosomal communication during tumor progression and contributes to the detailed understanding of metastatic processes.
Bibliography:Edited by: Fabrizio Mattei, National Institute of Health (ISS), Italy
Reviewed by: Kawaljit Kaur, University of California, Los Angeles, United States; Fatemeh Momen-Heravi, Columbia University, United States
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2019.02459